Annual CFI
$268.73 M
+$485.39 M+224.03%
December 31, 2023
Summary
- As of February 7, 2025, SUPN annual cash flow from investing activities is $268.73 million, with the most recent change of +$485.39 million (+224.03%) on December 31, 2023.
- During the last 3 years, SUPN annual CFI has risen by +$303.43 million (+874.46%).
- SUPN annual CFI is now at all-time high.
Performance
SUPN Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$77.01 M
-$28.42 M-58.48%
September 30, 2024
Summary
- As of February 7, 2025, SUPN quarterly cash flow from investing activities is -$77.01 million, with the most recent change of -$28.42 million (-58.48%) on September 30, 2024.
- Over the past year, SUPN quarterly CFI has dropped by -$111.64 million (-322.36%).
- SUPN quarterly CFI is now -132.12% below its all-time high of $239.78 million, reached on March 31, 2023.
Performance
SUPN Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$243.21 M
-$111.64 M-84.86%
September 30, 2024
Summary
- As of February 7, 2025, SUPN TTM cash flow from investing activities is -$243.21 million, with the most recent change of -$111.64 million (-84.86%) on September 30, 2024.
- Over the past year, SUPN TTM CFI has dropped by -$529.15 million (-185.05%).
- SUPN TTM CFI is now -185.05% below its all-time high of $285.94 million, reached on September 30, 2023.
Performance
SUPN TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
SUPN Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +224.0% | -322.4% | -185.1% |
| 3 y3 years | +874.5% | -322.4% | -185.1% |
| 5 y5 years | +165.0% | -322.4% | -185.1% |
SUPN Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +224.0% | -132.1% | +6.3% | -185.1% | at low |
| 5 y | 5-year | at high | +224.0% | -132.1% | +28.8% | -185.1% | at low |
| alltime | all time | at high | +165.0% | -132.1% | +81.8% | -185.1% | +52.6% |
Supernus Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$77.01 M(+58.5%) | -$243.21 M(+84.9%) |
| Jun 2024 | - | -$48.59 M(-5.9%) | -$131.56 M(+480.2%) |
| Mar 2024 | - | -$51.62 M(-21.8%) | -$22.68 M(-108.4%) |
| Dec 2023 | $268.73 M(-224.0%) | -$65.98 M(-290.5%) | $268.73 M(-6.0%) |
| Sep 2023 | - | $34.63 M(-42.6%) | $285.94 M(+69.1%) |
| Jun 2023 | - | $60.30 M(-74.9%) | $169.08 M(+81.6%) |
| Mar 2023 | - | $239.78 M(-591.7%) | $93.10 M(-143.0%) |
| Dec 2022 | -$216.66 M(+164.5%) | -$48.77 M(-40.7%) | -$216.66 M(+136.1%) |
| Sep 2022 | - | -$82.23 M(+424.5%) | -$91.77 M(+502.2%) |
| Jun 2022 | - | -$15.68 M(-77.6%) | -$15.24 M(-81.1%) |
| Mar 2022 | - | -$69.99 M(-191.9%) | -$80.45 M(-1.8%) |
| Dec 2021 | -$81.91 M(+136.1%) | $76.13 M(-1434.7%) | -$81.91 M(-24.6%) |
| Sep 2021 | - | -$5.70 M(-92.9%) | -$108.70 M(-4.9%) |
| Jun 2021 | - | -$80.89 M(+13.2%) | -$114.30 M(-19.3%) |
| Mar 2021 | - | -$71.44 M(-244.8%) | -$141.58 M(+308.0%) |
| Dec 2020 | -$34.70 M(-78.0%) | $49.34 M(-536.6%) | -$34.70 M(-46.3%) |
| Sep 2020 | - | -$11.30 M(-89.6%) | -$64.61 M(+4.8%) |
| Jun 2020 | - | -$108.18 M(-405.3%) | -$61.66 M(+220.5%) |
| Mar 2020 | - | $35.44 M(+82.3%) | -$19.24 M(-87.8%) |
| Dec 2019 | -$157.92 M(-61.8%) | $19.44 M(-332.7%) | -$157.92 M(+10.4%) |
| Sep 2019 | - | -$8.36 M(-87.3%) | -$143.03 M(+30.8%) |
| Jun 2019 | - | -$65.76 M(-36.3%) | -$109.34 M(-76.5%) |
| Mar 2019 | - | -$103.25 M(-400.7%) | -$465.72 M(+12.6%) |
| Dec 2018 | -$413.48 M(+378.5%) | $34.33 M(+35.5%) | -$413.48 M(-11.4%) |
| Sep 2018 | - | $25.34 M(-106.0%) | -$466.94 M(-9.1%) |
| Jun 2018 | - | -$422.14 M(+727.6%) | -$513.44 M(+340.1%) |
| Mar 2018 | - | -$51.01 M(+166.7%) | -$116.66 M(+35.0%) |
| Dec 2017 | -$86.42 M | -$19.13 M(-9.6%) | -$86.42 M(+6.8%) |
| Sep 2017 | - | -$21.16 M(-16.6%) | -$80.93 M(+15.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | -$25.36 M(+22.2%) | -$70.12 M(+52.2%) |
| Mar 2017 | - | -$20.76 M(+52.2%) | -$46.08 M(+28.1%) |
| Dec 2016 | -$35.96 M(-8.5%) | -$13.64 M(+31.8%) | -$35.96 M(+2.2%) |
| Sep 2016 | - | -$10.35 M(+682.9%) | -$35.19 M(+4.7%) |
| Jun 2016 | - | -$1.32 M(-87.6%) | -$33.60 M(-13.4%) |
| Mar 2016 | - | -$10.65 M(-17.2%) | -$38.82 M(-1.2%) |
| Dec 2015 | -$39.29 M(+1377.6%) | -$12.87 M(+46.9%) | -$39.29 M(+14.3%) |
| Sep 2015 | - | -$8.76 M(+33.9%) | -$34.37 M(+37.0%) |
| Jun 2015 | - | -$6.54 M(-41.2%) | -$25.09 M(+106.5%) |
| Mar 2015 | - | -$11.12 M(+39.8%) | -$12.15 M(+356.9%) |
| Dec 2014 | -$2.66 M(-78.0%) | -$7.95 M(-1617.7%) | -$2.66 M(-110.1%) |
| Sep 2014 | - | $524.00 K(-91.8%) | $26.20 M(-13.5%) |
| Jun 2014 | - | $6.40 M(-492.8%) | $30.29 M(-385.9%) |
| Mar 2014 | - | -$1.63 M(-107.8%) | -$10.59 M(-12.5%) |
| Dec 2013 | -$12.11 M(-75.3%) | $20.91 M(+354.0%) | -$12.11 M(-71.4%) |
| Sep 2013 | - | $4.61 M(-113.4%) | -$42.37 M(-26.0%) |
| Jun 2013 | - | -$34.48 M(+994.9%) | -$57.28 M(+87.5%) |
| Mar 2013 | - | -$3.15 M(-66.3%) | -$30.55 M(-37.6%) |
| Dec 2012 | -$48.96 M(-244.4%) | -$9.35 M(-9.3%) | -$48.96 M(+245.2%) |
| Sep 2012 | - | -$10.30 M(+32.8%) | -$14.18 M(-319.4%) |
| Jun 2012 | - | -$7.76 M(-64.0%) | $6.46 M(-64.2%) |
| Mar 2012 | - | -$21.55 M(-184.8%) | $18.05 M(-46.8%) |
| Dec 2011 | $33.90 M(+31.3%) | $25.43 M(+145.9%) | $33.90 M(+300.2%) |
| Sep 2011 | - | $10.34 M(+170.0%) | $8.47 M(-552.8%) |
| Jun 2011 | - | $3.83 M(-167.2%) | -$1.87 M(-67.2%) |
| Mar 2011 | - | -$5.70 M | -$5.70 M |
| Dec 2010 | $25.82 M(-191.0%) | - | - |
| Dec 2009 | -$28.39 M(-283.4%) | - | - |
| Dec 2008 | $15.48 M(+4.2%) | - | - |
| Dec 2007 | $14.85 M | - | - |
FAQ
- What is Supernus Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual CFI year-on-year change?
- What is Supernus Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly CFI year-on-year change?
- What is Supernus Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals TTM CFI year-on-year change?
What is Supernus Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of SUPN is $268.73 M
What is the all time high annual CFI for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual cash flow from investing activities is $268.73 M
What is Supernus Pharmaceuticals annual CFI year-on-year change?
Over the past year, SUPN annual cash flow from investing activities has changed by +$485.39 M (+224.03%)
What is Supernus Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of SUPN is -$77.01 M
What is the all time high quarterly CFI for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly cash flow from investing activities is $239.78 M
What is Supernus Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, SUPN quarterly cash flow from investing activities has changed by -$111.64 M (-322.36%)
What is Supernus Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of SUPN is -$243.21 M
What is the all time high TTM CFI for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high TTM cash flow from investing activities is $285.94 M
What is Supernus Pharmaceuticals TTM CFI year-on-year change?
Over the past year, SUPN TTM cash flow from investing activities has changed by -$529.15 M (-185.05%)